The Asian Scientist 100
Lu Ke
Institution
Chinese Academy of Sciences
Country
China
Field
Materials Sciences
Lu is the winner of the 2020 Future Science Prize (Physical Science Prize) for discovering and synthesizing a superior nanotwinned structure and gradient nanostructure.
(Photo: Future Science Prize)
AWARDS
- Future Science Prize 2020
Related articles
Unveiling A Molecule That Gives Malaria A ‘Cloak Of Invisibility’
Australian researchers have discovered a molecule called PfSET10 that is key to malaria’s ‘invisibility cloak.’
Study: Chinese Herb Dihydromyricetin Stops Hangovers, Alcohol Dependency In Rats
UCLA researchers have shown that an ancient Chinese herbal drug stops hangovers and reduces alcohol dependency in rats.
Australia, New Zealand Are World’s Largest Users Of Cannabis & Amphetamines
Australia and New Zealand have the highest rates of cannabis and amphetamine use in the world, according to comprehensive research on illicit drug use.
Nepal’s Monsanto Seed Sovereignty Debate Highlights Need For Home-Grown Solutions
An effort by U.S. donors and Monsanto to partner with Nepal to boost local maize production with imported hybrid seeds has met civil society opposition calling - instead - for home-grown solutions.
World’s Tiniest Frog, Paedophryne Amauensis, Found In Papua New Guinea
Researchers have found two new frog species in New Guinea, one of which is the new smallest known vertebrate on Earth.
Australian Study To Assess Sativex As Cannabis Withdrawal Drug
Researchers are studying whether the pharmaceutical drug Sativex - registered for pain relief in multiple sclerosis patients - can help people better manage cannabis withdrawal symptoms as well.
Vivo Ventures To Invest US$1 Billion In U.S. And China Healthcare Companies
Vivo plans to invest its US$1 billion fund primarily in later development stage pharmaceutical and medical device companies in the U.S. and in revenue stage healthcare companies in greater China.
UNICEF Launches Schools For Asia To Improve Education For Millions
UNICEF reports on a new fundraising initiative called Schools for Asia, to transform children’s lives through education.
SFJ Pharma To Conduct Phase III Trial Of Pfizer’s Axitinib Adjuvant Treatment In Asia
SFJ Pharma Ltd. will conduct a Phase III clinical trial in Asia of Pfizer's axitinib for the adjuvant treatment of patients at high risk of recurrent renal cell carcinoma following nephrectomy.